Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment.
Latagliata R, Niscola P, Fianchi L, Aloe Spiriti MA, Maurillo L, Carmosino I, Cesini L, Sarlo C, Piccioni A, Campagna A, De Luca ML, De Benedittis D, Mancini M, Breccia M, Criscuolo M, Buccisano F, Voso MT, Avvisati G, Tafuri A, De Fabritiis P, Foà R, Girmenia C. Latagliata R, et al. Among authors: sarlo c. Hematol Oncol. 2020 Apr;38(2):189-196. doi: 10.1002/hon.2710. Epub 2020 Jan 23. Hematol Oncol. 2020. PMID: 31891213
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Maurillo L, Buccisano F, Spagnoli A, Del Poeta G, Panetta P, Neri B, Del Principe MI, Mazzone C, Consalvo MI, Tamburini A, Ottaviani L, Fraboni D, Sarlo C, De Fabritiis P, Amadori S, Venditti A. Maurillo L, et al. Among authors: sarlo c. Haematologica. 2007 May;92(5):605-11. doi: 10.3324/haematol.10432. Haematologica. 2007. PMID: 17488683 Free article.
Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes.
Buccisano F, Maurillo L, Tamburini A, Del Poeta G, Del Principe MI, Ammatuna E, Consalvo MI, Campagna S, Ottaviani L, Sarlo C, Renzi D, Faccia S, Fraboni D, Lo Coco F, Amadori S, Venditti A. Buccisano F, et al. Among authors: sarlo c. Eur J Haematol. 2008 Feb;80(2):107-14. doi: 10.1111/j.1600-0609.2007.00986.x. Epub 2007 Nov 17. Eur J Haematol. 2008. PMID: 18028430
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
Maurillo L, Buccisano F, Del Principe MI, Del Poeta G, Spagnoli A, Panetta P, Ammatuna E, Neri B, Ottaviani L, Sarlo C, Venditti D, Quaresima M, Cerretti R, Rizzo M, de Fabritiis P, Lo Coco F, Arcese W, Amadori S, Venditti A. Maurillo L, et al. Among authors: sarlo c. J Clin Oncol. 2008 Oct 20;26(30):4944-51. doi: 10.1200/JCO.2007.15.9814. Epub 2008 Jul 7. J Clin Oncol. 2008. PMID: 18606980 Free article.
Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia.
Buccisano F, Maurillo L, Spagnoli A, Del Principe MI, Fraboni D, Panetta P, Ottone T, Consalvo MI, Lavorgna S, Bulian P, Ammatuna E, Angelini DF, Diamantini A, Campagna S, Ottaviani L, Sarlo C, Gattei V, Del Poeta G, Arcese W, Amadori S, Lo Coco F, Venditti A. Buccisano F, et al. Among authors: sarlo c. Blood. 2010 Sep 30;116(13):2295-303. doi: 10.1182/blood-2009-12-258178. Epub 2010 Jun 14. Blood. 2010. PMID: 20548095 Free article. Clinical Trial.
Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes.
Buccisano F, Maurillo L, Neri B, Masala S, Mauriello A, Del Principe MI, Ditto C, Sarlo C, Cefalo M, Di Caprio L, Loreni G, Cicconi L, Amadori S, Venditti A. Buccisano F, et al. Among authors: sarlo c. J Clin Oncol. 2013 Apr 10;31(11):e189-91. doi: 10.1200/JCO.2012.45.3209. Epub 2013 Feb 19. J Clin Oncol. 2013. PMID: 23423741 No abstract available.
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy.
Sarlo C, Buccisano F, Maurillo L, Cefalo M, Di Caprio L, Cicconi L, Ditto C, Ottaviani L, Di Veroli A, Del Principe MI, Grasso MA, Nasso D, De Santis G, Amadori S, Venditti A. Sarlo C, et al. Leuk Res Treatment. 2013;2013:705714. doi: 10.1155/2013/705714. Epub 2013 Apr 28. Leuk Res Treatment. 2013. PMID: 23738080 Free PMC article.
Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.
Maurillo L, Buccisano F, Del Principe MI, Sarlo C, Di Caprio L, Ditto C, Giannotti F, Nasso D, Ceresoli E, Postorino M, Refrigeri M, Amadori S, Venditti A. Maurillo L, et al. Among authors: sarlo c. Mediterr J Hematol Infect Dis. 2013 Jun 3;5(1):e2013032. doi: 10.4084/MJHID.2013.032. Print 2013. Mediterr J Hematol Infect Dis. 2013. PMID: 23795270 Free PMC article.
33 results